Singapore
-
Everest Medicines expands Asia-Pacific footprint with US$250M Hasten Biopharmaceuticals acquisition
EverSea Medicines will make an initial payment of US$150 million at closing, followed by two additional payments of US$50 million each, scheduled for the first quarters of 2028 and 2029, subject to agreed conditions.
-
BioNTech closes Singapore manufacturing plant as COVID-19 vaccine demand collapses
BioNTech’s decision follows a comprehensive strategic review aimed at aligning the company’s manufacturing capacity with its clinical pipeline and long-term business direction
-
Singapore earns top WHO rating for medical device regulation
The recognition provides an important reference point for other countries working to strengthen their regulatory systems.
-
Fullerton Health acquires The ENT Clinic to expand specialist care in Singapore
This acquisition expands Fullerton Health’s network of high-quality specialist care throughout Southeast Asia.
-
Singapore approves Respiree’s AI-powered patient monitoring system for detecting acute deterioration
The newly approved toolbox serves as a sophisticated aid for healthcare professionals who need to identify signs of acute deterioration in their inpatient populations.